Results 221 to 230 of about 152,141 (270)
Hepatitis D Virus Pathogenesis: A Sense of Complications. [PDF]
Haennel Y, Baumert TF, Lupberger J.
europepmc +1 more source
ABSTRACT Background There is compelling evidence that treating high‐grade squamous intraepithelial lesions (HSIL), the anal squamous cell cancer (ASCC) precursor, reduces the risk of developing ASCC. Using high‐resolution anoscopy (HRA), surgical excision, ablative and topical therapies are widely used to treat HSIL.
Matthew Joseph Marino +5 more
wiley +1 more source
Innate and adaptive immune responses in Hepatitis C virus infections. [PDF]
Kishida Y.
europepmc +1 more source
Comparative MRI of in vivo kidneys and ex vivo donor kidneys during NMP revealed marked physiological differences and limited correspondence with conventional perfusion or injury metrics. These distinct ex vivo MRI signatures emphasize the need to consider parameters beyond conventional in vivo functional markers when assessing organ viability during ...
Tim L. Hamelink +12 more
wiley +1 more source
Comparative analysis of ducks liver gene expressions infected with virulent or attenuated DHAV-3 reveals divergent host responses to viruses of different virulence. [PDF]
Fu Q +10 more
europepmc +1 more source
When serology misleads: cross-reactivity in acute hepatitis. [PDF]
Nowak K +5 more
europepmc +1 more source
A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz +17 more
wiley +1 more source
Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity. [PDF]
Medeiros CMDS +4 more
europepmc +1 more source
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo +13 more
wiley +1 more source

